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Abstract
Background: X-linked ocular albinism type 1 (OA1) is caused by mutations in OA1 gene, which
encodes a membrane glycoprotein localised to melanosomes. OA1 mainly affects pigment
production in the eye, resulting in optic changes associated with albinism including
hypopigmentation of the retina, nystagmus, strabismus, foveal hypoplasia, abnormal crossing of the
optic fibers and reduced visual acuity. Affected Caucasian males usually appear to have normal skin
and hair pigment.
Results:  We identified three previously undescribed mutations consisting of two intragenic
deletions (one encompassing exon 6, the other encompassing exons 7–8), and a point mutation
(310delG) in exon 2. We report the development of a new method for diagnosis of heterozygous
deletions in OA1 gene based on measurement of gene copy number using real-time quantitative
PCR from genomic DNA.
Conclusion: The identification of OA1 mutations in families earlier reported as families with
hereditary nystagmus indicate that ocular albinism type 1 is probably underdiagnosed. Our method
of real-time quantitative PCR of OA1 exons with DMD exon as external standard performed on the
LightCycler™ allows quick and accurate carrier-status assessment for at-risk females.
Background
Congenital nystagmus (CN) is the common symptom of
a range of diseases involving the macula from infancy on,
and includs at least three X-linked disorders: Nettleship-
Falls ocular albinism type 1 (OA1; MIM#300500)
mapped to Xp22.3, complete congenital stationary night
blindness (CSNB1; MIM#310500), mapped to Xp11.3
and blue-cone monochromatism (CBBM; MIM#303700),
mapped to Xq28. These genetic disorders must be distin-
guished from the congenital motor nystagmus (CMN), a
hereditary disorder characterized by bilateral ocular oscil-
lations which occurs in the absence of any apparent ocular
disease [1]. Diagnosis of the underlying disease often re-
quires extensive clinical and electrophysiological exami-
nations. Prevalence of OA1 is estimated around 1 in
50,000 live births in Caucasian populations. The most fre-
quent findings in hemizygous individuals with OA1 are
foveal hypoplasia, hypopigmentation of the retina and
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iris translucency together with normally pigmented skin
and hair [2]. The disease typically results in severely im-
paired visual acuity in affected males who also manifest
variable strabismus, photophobia, and misrouting of op-
tic pathway. The size, shape and number of melanocytes
are normal in the skin, hair follicle and retinal pigment
epithelium in OA1 patients, but they contain (although
not specifically) variable proportions of giant melano-
somes [3]. In spite of a well-defined clinical presentation,
a few individuals initially misdiagnosed with congenital
nystagmus have been shown to be affected by ocular albi-
nism type 1 by screening the OA1 gene [3,4]. We report on
three additional white OA1 unrelated families, with a to-
tal of fourty seven individuals, which were initially re-
ferred to our laboratory for congenital nystagmus. The
aim of the study was to elucidate the molecular genetic de-
fect responsible for the phenotype and to define a reliable
strategy to assess the genetic status of at-risk females.
Results and discussion
Analysis of X-linked markers in the two pedigrees (OA1-1
and OA1-2) initially reported as familial cases diagnosed
with X-linked congenital nystagmus was consistent with
an association between the affected phenotype and the
OA1 locus, as exemplified in Fig. 1 for a microsatellite in
OA1 intron 1. OA1 gene was then extensively screened,
and the disease-causing mutation could be identified in
the three families reported in this study.
Two novel OA1 gene deletions
The OA1 gene was then examined for mutations, and we
detected one deletion encompassing exons 7–8 (pedigree
OA1-1), and one deletion encompassing exon 6 (pedigree
Figure 1
Pedigrees initially referred for congenital X-linked nystagmus.Black squares are for affected males, small solid circle 
within open circles for obligate carrier females, open symbols for non affected individuals. ?: undefined clinical status prior to 
doing molecular study. Numbered individuals are those in whom molecular investigation of the OA1 gene was performed. 
Results of the OA1-CA microsatellite analysis are given in families OA1-1 and OA1-2 as indicated by alleles A, B, C, or D.
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OA1-2). The amplification failure was shown to be specif-
ic for this portion of the OA1 gene by using duplex-PCR.
In pedigree OA1-1, exons 7 and 8 were co-amplified with
OA1 exons 9 and 6, respectively (Fig. 2A). In pedigree
OA1-2, exon 6 was co-amplified with OA1 exon 9 (Fig.
2B). Moreover, the single exon 6 deletion was confirmed
using alternative primers to exclude possible sequence
changes in primer annealing sites.
As heterozygous deletions are not detected by convention-
al PCR, assessment of genetic status in females was per-
formed by using two complementary strategies.
Indirect analysis
A highly polymorphic dinucleotide repeat OA1-CA locat-
ed within intron 1 [5] was used for carrier testing in both
families. Segregation analysis using the OA1-CA marker in
the family OA1-2 showed that the sister (III2) of the af-
fected individuals had inherited the maternal allele (A)
that has been transmitted to the affected males (Fig. 1),
thus indicative of the sister to be a probable carrier of the
exon 6 deletion in the OA1 gene. In family OA1-1, the
analysis of marker OA1-CA revealed full cosegregation be-
tween one allele (B) of the dinucleotide repeat and the
disease (Fig. 1), which allowed to exclude one at-risk fe-
male (IV9) of being a carrier.
Establishment of a quantitative real-time PCR for OA1 gene dosage 
assay
Indirect analysis was not able to elucidate the carrier status
of two other females IV4 and IV8 in family OA1-1. We
therefore developed a quantitative test for detection of
heterozygous deletions on the basis of real-time PCR on a
LightCyclerTM instrument. The method involves amplifi-
cation of an exon included in the deletion (OA1-exon 8)
and normalization of genomic template by analyzing a
reference locus with known copy number. We used a frag-
ment (exon 4) of the DMD gene as reference locus because
it yielded previously highly reproducible amplification re-
sults. Heterozygosity for a deletion is expected to reduce
the gene dose from two to one in carriers. We detected an
OA1-exon 8/DMD-exon 4 ratio of 0.56 in female III8, thus
confirming the presence of the heterozygous deletion of
exon 8 in this obligate carrier, while the female and male
controls showed a ratio of approximately 1.0 (0.93 and
0.98, respectively) (Fig. 3). Gene dosage analysis in the
two females IV4 and IV8 whose carrier status was previ-
ously undefined clearly established that they were both
carriers of an exon 8 deletion (OA1-exon8/DMD-exon 4
ratio of 0.47 and 0.42, respectively).
A novel frameshift OA1 point mutation
In the index patient (IV1) of family OA1-3 that did not
show exon deletion, sequence analysis of all coding exons
including the exon-intron boundaries revealed a deletion
of a single nucleotide G at position 310 of the cDNA in-
Figure 2
Detection of OA1 intragenic deletions in males. (A) Exon 7 (top) and exon 8 (bottom) failed to amplify in two affected 
males III2 and V1 from family OA1-1 while the two exons amplified normally from DNA obtained from unaffected individuals 
(III1, III3, IV1) and a female carrier (IV2). As internal control, exon 9 of the OA1 gene has simultaneously amplified from the 
DNA samples of family members. (B) A deletion of exon 6, using primers 6H6F and 6H6R [5], was detected in the proband III1 
of family OA1-2. The deletion of exon 6 was found in all affected individuals of the family (I1, III1, III3, and III4). Alternative 
primers were used to confirm the deletion (data not shown). M: molecular weight marker, one kilobase ladder, Gibco BRL.
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troducing a subsequent premature stop codon one codon
downstream, predicting a deleterious protein product.
This newly described mutation (310delG) in exon 2 of the
OA1 gene creates a TaqI restriction site. Although the ped-
igree of family OAI-3 initially suggested the patient IV1 to
be a sporadic case, PCR-restriction analysis identified the
patient's maternal uncle (III3), known to have only a de-
creased visual acuity at age 38, as hemizygous for the mu-
tation. The mother (III2) and the maternal grand-mother
(II1) of the proband were found to be carriers (Fig. 4B), as
expected, while the great-grandmother (I1) showed a nor-
mal pattern of PCR restriction, which is indicative either
of a de novo mutation in her germline or inheritance of the
mutation from her deceased husband.
Different prevalences of intragenic OA1  deletions have
been reported, ranging from 8% to 50% in different stud-
ies [6,7]. As approximately 50% of the OA1 mutations re-
ported to date [7], the three mutations described in this
study lead to a truncated OA1 protein and, presumably, to
a complete loss of function. Several missense mutations
have also been described in OA1 which result in defective
intracellular transport and glycosylation due to misfold-
ing of the protein [8]. OA1 encodes a seven helix mem-
brane G protein coupled receptor (GPCR) localized to the
membrane of intracellular organelles, namely the
melanosomes in pigment cells [3,9]. OA1 is thought to be
involved in the regulation of biogenesis and maturation
of melanosomes through activation of heterotrimeric G
proteins on the cytoplasmic side of melanosomal mem-
brane [8]. The aberrant pigment production associated
with OA1 could be caused by a defect in a yet unidentified
intracellular signal transduction system that regulates the
growth of melanosomes [3,10,11]
Conclusions
The three mutations reported here have been found in pa-
tients who were initially misdiagnosed with congenital
nystagmus when they where examined first. Our observa-
tion is in agreement with previous report by Rosenberg
Figure 3
Real-Time Fluorescent PCR Gene Dosage Test. Segregation of the deletion of exons 7–8 in pedigree OA1-1 was dem-
onstrated by quantitative screening using the Light Cycler™ technology. Results of dosage of the DMD-exon 4 (reference 
locus) and OA1-exon 8 (test locus) are shown on the histogram (white bars and grey bars, respectively). Each DNA sample was 
run in quadruplicate. Errors bars indicate standard deviation. Mean values of dosages and ratios [OA1-exon 8 (test) DMD-exon 
4] are given in the Table. Lane 1, normal control female; lane 2, normal male; lane 4, obligate carrier of the exons 7–8 deletion 
(ratio test/ref of 0.56). Lanes 3 and 5, females IV4 and IV8 (with undefined status initially) showing a heterozygous deletion of 
OA1-exon 8 indicated by ratios of approximately 0.5.
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and Schwartz. [9] who stated that ocular albinism type 1
is underdiagnosed and pinpoints the fact that the clinical
investigation of patients in specialized consultation may
be required for accurate and differential diagnosis of OA1.
The female carriers are usually asymptomatic, but have
been reported to exhibit punctuate areas of iris transillu-
mination defects and a characteristic mottled appearance
of the retinal pigment epithelium resulting from Lyonisa-
tion [12]. Also, the identification of macromelanosomes
on skin biopsy can be useful for supporting the diagnosis
and identifying carriers eventhough it is not a specific and
obligate criteria [4]. However, if clinical examination will
detect approximately 70 % of carrier females, it will not al-
low reliable genetic counselling for all at-risk females be-
cause of the variability in clinical manifestations. Reliable
carrier determination can be achieved by molecular stud-
ies as presented in this study. It relies on different molec-
ular approaches depending on the familial history
(familial versus sporadic cases) and the type of the muta-
tion (point mutation versus large deletions). In familial
cases with unidentified OA1 mutations, indirect approach
based on linkage analysis using microsatellites may be of
help but requires extensive familial DNA analysis and
may be unconclusive in some individuals. Direct testing
of previously characterized point mutations in at risk fe-
males can be performed either by direct sequencing or by
scanning methods such as DGGE (Denaturing Gradient
Gel Electrophoresis) or dHPLC (denaturing High Per-
formance Liquide Chromatography), although these
methods may be more technically difficult to set up. For
detection of intragenic deletions in females, Southern
blotting is not the method of choice as it is time-consum-
ing, radioactive, and as estimation of gene dosage by
measuring the intensity of probe hybridized is not accu-
Figure 4
Caracterisation of the 310delG mutation in the family OA1-3. (A) Direct sequencing of the OA1 gene exon 2 showing 
a one-bp deletion in the index case (bottom) compared with the wild-type sequence (top). (B) Familial segregation of the 
310delG mutation is illustrated by restriction analysis. The mutation creates a new restriction site for TaqI, which cleaves the 
204-bp exon 2 PCR product into two fragments (104 and 100 bp) in III3 and IV1, showing a heterozygous pattern in the carrier 
females II1 and III2. M: molecular weight marker, one kilobase ladder, Gibco BRL.
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rate enough. The real-time fluorescent PCR gene dosage
assay that we have developed in this study is an accurate,
non radioactive and fast method for gene carrier assess-
ment that can be applied to any type of OA1 gene dele-
tion.
Methods
Families
Affected males in pedigrees OA1-1, OA1-2, and OA1-3
were initially diagnosed with congenital nystagmus inher-
ited in an X-linked pattern, and blood samples from 47 in-
dividuals were referred to our laboratory for genotyping in
the purpose to identify the genetic interval with which a
putative gene could be located. Blood samples were taken
from patients and available family members after in-
formed consent, and genomic DNA was isolated by stand-
ard techniques. All individuals were Caucasians
originating from South of France.
Clinical examination
Congenital nystagmus was diagnosed in individuals IV3
in pedigree OA1-1, I1, III1 and III3 in pedigree OA1-2 and
IV1 in pedigree OA1-3 following routine ophthalmologi-
cal examination. The patients had normal hair and skin
pigmentation. There was no photophobia or nyctalopia.
After identification of a mutation in the OA1 gene, clinical
signs were re-evaluated. Kinetic visual fields were deter-
mined in a Goldman perimeter with targets V4e, III4e, et
I4e. Full-fields ERG was recorded using a ganzfeld appara-
tus (Metrovision, France) with a bipolar contact lens elec-
trode on maximally dilated pupils. Ophthalmological
examination revealed signs consistent with ocular albi-
nism type 1 in all affected males re-examined.
In family OA1-1 the affected male IV3, aged 10 at the time
of presentation, had a visual acuity of 30/200 in RE (+2.50
sph/+1.50 cyl A 70°) and 40/200 in LE (+2.50 sph/+1.00
A 180°). At slit-lamp examination there was no abnor-
mality of the iris pigmentation and the lenses were trans-
parent. The fundus revealed a patchy aspect of the
pigmentation in peripheral retina with some areas of hy-
popigmentation. There was a foveal hypoplasia that was
confirmed by the absence of the normal afluorescence of
the macula.
In family OA1-2, the 9-year old proband III4 had a visual
acuity of 40/200 in both eyes. Slit-lamp examination re-
vealed retroillumination of the iris periphery. The lenses
were transparent. Fundus examination showed a slight de-
pigmentation with moderate foveal hypoplasia. The 44
year-old mother (II2) who was also examined had 20/20
of visual acuity in both eyes and normal iris pigmenta-
tion; however, fundus examination revealed a patchy pig-
mentation at the posterior pole and numerous, low
contrasted gray dots in the mid periphery of the retinas.
The apparently sporadic case IV2 in family OA1-3 had, at
26 years of age, a visual acuity of 30/200 in both eyes with
RE (+3.00 sph/3.50 cyl A 180°) and LE (+4.25 sph/2.75
cyl A 180°). Slit-lamp examination revealed a spoke like
atrophy of the iris with retroillumination. The lenses were
transparent and the intraocular pressure was 14 (RE) and
15 (LE). Fundus examination showed a radial pattern of
hypopigmentation that spared the macula. There was
foveal hypoplasia with some retinal vessels that crossed
the macular area, confirmed by the absence of the normal
afluorescence of the macula. ERG recording of the mixed
rod-cone response was in the normal range but the rod re-
sponse was slightly diminished and the cone response
(30-Hz flickers) was markedly diminished.
Skin biopsy was unavailable for any patient at the time of
the study.
Linkage analysis
X chromosome marker set (Panel 28) from the ABI PRISM
Linkage Mapping set MD-10 (Applied Biosystems) was
used. Markers were amplified from genomic DNA, accord-
ing to methods specified by the manufacturers. PCR prod-
ucts were loaded onto an ABI 377 automated sequencer,
and data were analyzed by ABI GeneScan 3.5 and Genoty-
per softwares.
Screening OA1 gene for mutations
All nine exons of the OA1 gene and part of the flanking in-
trons were PCR-amplified from genomic DNA using the
primers described by Schiaffino et al. [5], with some mod-
ifications. A new forward primer was used for exon 3 am-
plification (5'-TGACCTTTCCAGAGCGCAG-3'). Also, new
primers were designed to confirm the single exon 6 dele-
tion in family OA1-2 (forward 5'-GCCTTGCTTGT-
GGGCTCACA-3'; reverse 5'-
TCAAAGGGCACCTAGCACAGTCT-3'). PCR products of
the 9 exons were sequenced on both strands using the
BigDye terminator cycle sequencing kit (Applied Biosys-
tems, Foster City, CA) and analyzed on an ABI 310 auto-
mated sequencer with the sequence analysis software,
according to the manufacturer's protocols.
Carrier status determination
Restriction analysis
The PCR products were digested with 10 units of the ap-
propriate restriction enzyme, resolved on NuSieve agarose
gels, and visualized with ethidium bromide.
Indirect diagnosis using OA1-CA repeat
The dinucleotide repeat sequence was amplified using
primers and PCR conditons previously described [5]. Flu-Publish with BioMed Central    and   every 
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orescent PCR products were analyzed on an ABI 310 auto-
mated sequencer.
Gene dosage analysis in family OA1-2
The quantification was performed with a LightCycler in-
strument (Roche Diagnostics) using SYBR Green I for on-
line measurement of PCR products. The method involves
amplifications of a test exon located within the deleted re-
gion (OA1 exon 8) with unknown copy number and a ref-
erence locus (exon 4 of the X-linked DMD gene) with
known copy number. Using standard curves, the copy
number of the test DNA relative to a common standard
DNA is determined for each locus. From the ratio of the
relative copy numbers, the genomic copy number of the
test locus is determined. In each assay, 3 family members,
2 normal controls (male and female), and a no-template
control (background) were included. Each sample was
run in quadruplicate. The PCR was performed in a total
volume of 20 µl, containing 4 pmol of each primer, 2 µl
of Faststart DNA kit SYBR Green I, 5 mM MgCl2. The reac-
tions were cycled 45 times with a 95°C denaturation for
15 sec, a 55°C (OA1 exon 8) or 65°C (DMD exon 4) an-
nealing for 5 sec, and 72°C extension for 10 sec (DMD
exon 4) or for 15 sec (OA1 exon 8). The primer sequences
for OA1-exon 8 and DMD-exon 4 have been previously
described [5,13]. This quantification program was fol-
lowed by a melting program for every PCR product for
each sample. Quantification data were analyzed using the
fit points method of the LightCycler software.
List of abbrevation
OA1: ocular albinism type 1
PCR: polymerase chain reaction
CN: congenital nystagmus
CSNB: complete congenital stationary night blindness
CBBM: blue-cone monochromatism
CMN: congenital motor nystagmus
DMD: duchenne muscular dystrophy
GPCR: G protein coupled receptor
ERG: electroretinography
DGGE: denaturing gradient gel electrophoresis
DHPLC: denaturing high performance liquide chroma-
togrphy
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